Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants

Background: The neutralizing ability of sotrovimab and casirivimab/imdevimab against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is attenuated in the subvariant BA.5. However, the efficacy of sotrovimab in the clinical setting remains to be investigated. Methods: Patients admitt...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimoto, Kana, Mutsuo, Satoru, Yasuda, Yuto, Arasawa, Soichi, Tashima, Noriyuki, Iwashima, Daisuke, Takahashi, Ken-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778297/
https://www.ncbi.nlm.nih.gov/pubmed/36547245
http://dx.doi.org/10.3390/idr14060099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778297/
https://www.ncbi.nlm.nih.gov/pubmed/36547245
http://dx.doi.org/10.3390/idr14060099

Ejemplares similares